Efficacy and safety of voriconazole as invasive fungal infection prophylaxis in patients with acute myeloid leukemia-Reference-Cited by-同舟云学术

Efficacy and safety of voriconazole as invasive fungal infection prophylaxis in patients with acute myeloid leukemia

Published:2022-05-13 Issue:10 Volume:63 Page:2330-2335
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Machherndl-Spandl Sigrid¹,Vockenhuber Thomas¹,Binder Michaela¹,Weltermann Ansgar¹,Apfalter Petra²,Lass-Flörl Cornelia³,Girschikofsky Michael¹

Affiliation:

1. Department of Internal Medicine I (Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology), Ordensklinikum Linz Elisabethinen, Linz, Austria

2. Institute of Hygiene, Microbiology and Tropical Medicine and analyse BioLab, National Reference Centre for Antimicrobial Resistance, IZIM – Ordensklinikum Linz Elisabethinen, Linz, Austria

3. Division of Hygiene and Medical Microbiology, Medical University of Innsbruck, Innsbruck, Austria

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2022.2068006

Reference20 articles.

1. Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO)

2. Posaconazole vs. Fluconazole or Itraconazole Prophylaxis in Patients with Neutropenia

3. Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antifungals/antineoplastics;Reactions Weekly;2023-06-24

2. Prolonged duration of lymphocyte deficiency, high-grade CRS, and ventilation are linked to fungal breakthrough in patients with hematologic malignancies 60 days after CAR-T infusion: A single center case-control study;Journal of Infection and Public Health;2022-12